Ind-Swift Laboratories Limited (BOM:532305)
India · Delayed Price · Currency is INR 390.85
-9.15 (-2.29%)
At close: Oct 7, 2026
Ind-Swift Laboratories Revenue
Ind-Swift Laboratories had revenue of 1.91B INR in the quarter ending June 30, 2026, with 25.35% growth. This brings the company's revenue in the last twelve months to 6.74B, up 18.86% year-over-year. In the fiscal year ending March 31, 2026, Ind-Swift Laboratories had annual revenue of 6.49B with 13.04% growth.
Revenue (ttm)
6.74B
Revenue Growth
+18.86%
P/S Ratio
5.04
Revenue / Employee
4.86M
Employees
1,388
Market Cap
34.01B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 6.49B | 748.97M | 13.04% |
| Mar 31, 2025 | 5.74B | -11.35B | -66.40% |
| Mar 31, 2024 | 17.09B | 4.93B | 40.56% |
| Mar 31, 2023 | 12.16B | 1.63B | 15.48% |
| Mar 31, 2022 | 10.53B | 1.46B | 16.12% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| IOL Chemicals and Pharmaceuticals | 25.24B |
| Neuland Laboratories | 23.72B |
| Shilpa Medicare | 16.83B |
| Symbiotec Pharmalab | 8.84B |
| Bajaj HealthCare | 6.28B |
| NGL Fine-Chem | 5.36B |
| Aarey Drugs & Pharmaceuticals | 4.15B |
| Gujarat Themis Biosyn | 1.74B |
Ind-Swift Laboratories News
- 7 months ago - Ind-Swift Laboratories steps up export push with Rs 40 crore Jammu facility upgrade - Business Upturn